Cullinan Therapeutics, Inc. - Common Stock (NQ:CGEM)

Cullinan Therapeutics to Participate in Upcoming Investor Conferences

November 09, 2026

Velinotamig, a BCMAxCD3 T Cell Engager, Achieves Complete Renal Responses and Significantly Reduces Disease Activity in Systemic Lupus Erythematosus in Data Presented at ACR Convergence 2026

Performance

52-Week Range 56.1% below 52-week high

10.19

7.2552W Low 23.1952W High

1 Week 18.3% below 1-week high

10.691W Low 12.471W High

Cullinan Therapeutics, Inc. - Common Stock (CGEM) traded between $7.25 and $23.19 over the past 52 weeks and last traded at $10.19, 56.1% below its 52-week high. Over the past week it ranged between $10.69 and $12.47.

Past 12 Months

-5.6%

-31.8%

-48.0%

-37.6%

+0.7%

+30.6%

1W -$0.61

1M -$4.76

3M -$9.41

6M -$6.14

YTD +$0.07

1Y +$2.39

CGEM was +30.6% over the past year, -37.6% over six months, +0.7% year to date, -5.6% in the last week.

12 Months vs Market

CGEM

+30.6%

DIA

+9.0%

SPY

+10.9%

QQQ

+10.7%

IWM

+14.0%

Over the past 12 months CGEM returned +30.6% versus DIA (Dow) +9.0%, SPY (S&P 500) +10.9%, QQQ (Nasdaq 100) +10.7% and IWM (Russell 2000) +14.0%.

Volume & Liquidity 1.17× 3-mo avg

Today 1,129,605 3-mo avg 963.7K

1.1M

806.7K

963.7K

972.0K

YTD

900.5K

950.9K

CGEM most recently traded 1,129,605 shares against a 3-month average daily volume of 963.7K.

More News

November 08, 2026

Cullinan Therapeutics Announces Presentations for CLN-049, a FLT3 T Cell Engager, and Velinotamig, a BCMA T Cell Engager, at the 68th ASH Annual Meeting

November 04, 2026

Cullinan Therapeutics (NASDAQ:CGEM) Shares Jump on Inline Q2 Earnings and Pipeline Milestones ↗

August 06, 2026

Via Chartmill

3 Growth Stocks Under $20 With Hard Catalyst Dates Ahead ↗

October 28, 2026

Via MarketBeat

Cullinan Therapeutics Advances Velinotamig into Global Clinical Development for Autoimmune Cytopenias Following IND Clearance by the U.S. FDA

October 27, 2026

Zipalertinib Demonstrates Clinically Meaningful Intracranial Antitumor Activity in Patients with NSCLC with EGFR Exon 20 Insertion or Uncommon EGFR Mutations and Active CNS Metastases

October 19, 2026

From Taiho Oncology, Inc.

Cullinan Therapeutics Announces First Patient Dosed in Planned Registrational Phase 2 Study of CLN-049 in Relapsed/Refractory Acute Myeloid Leukemia

October 08, 2026

New Drug Application Submission Initiated for Zipalertinib Plus Chemotherapy in First-Line EGFR Exon 20 Insertion Mutation NSCLC for Review Under FDA Real-Time Oncology Review Program

October 01, 2026

Cullinan Therapeutics Highlights Fourth Quarter 2026 Milestones Across Immunology and Oncology T Cell Engager Portfolio

Cullinan Therapeutics Eyes December Data Catalyst for CLN-978 and CLN-049 ↗

September 28, 2026

Via MarketBeat

September 24, 2026

Cullinan Therapeutics to Participate in the Stifel 2026 Virtual Immunology and Inflammation Forum

September 21, 2026

Cullinan Therapeutics to Host Virtual Analyst and Investor Event Today to Feature Zipalertinib Plus Chemotherapy Phase 3 REZILIENT3 Data Presented at the IASLC 2026 World Conference on Lung Cancer

September 14, 2026

Zipalertinib Plus Chemotherapy Demonstrates 6-Month Median Progression-Free Survival Benefit in REZILIENT3 Phase 3 Trial in First-Line EGFR Exon 20 Insertion Mutation Non-Small Cell Lung Cancer

September 13, 2026

From Taiho Oncology, Inc. and Taiho Pharmaceutical Co., Ltd. and Cullinan Therapeutics, Inc.

Cullinan Therapeutics to Host Virtual Analyst and Investor Event to Showcase Zipalertinib Plus Chemotherapy Phase 3 REZILIENT3 Data Presented at the IASLC 2026 World Conference on Lung Cancer

September 10, 2026

Zipalertinib Plus Chemotherapy First-Line Phase 3 REZILIENT3 Trial Data Selected for Presidential Symposium Presentation at the IASLC 2026 World Conference on Lung Cancer

August 19, 2026

From Taiho Oncology, Inc.

Zipalertinib Plus Chemotherapy Meets Primary Endpoint of Progression-Free Survival in Planned Interim Analysis of Phase 3 REZILIENT3 Trial in First-Line EGFR Exon 20 Insertion Mutation Non-Small Cell Lung Cancer

August 12, 2026

From Taiho Oncology, Inc.

Cullinan Therapeutics Provides Corporate Update and Reports Second Quarter 2026 Financial Results

August 06, 2026

Cullinan Therapeutics Announces Positive End-of-Phase 1 Meeting with FDA for CLN-049 and Advances Program to a Potentially Registrational Phase 2 Study in AML

July 28, 2026

Cullinan Therapeutics Shares New Clinical Data Across Its Portfolio of T Cell Engager Programs Targeting CD19 and BCMA in Autoimmune Diseases

June 10, 2026

Why Marvell Technology Shares Are Trading Higher By 7%; Here Are 20 Stocks Moving Premarket ↗

June 08, 2026

Via Benzinga

Cullinan Therapeutics Presents Initial Clinical Data for CLN-978, a CD19xCD3 T Cell Engager, at the EULAR 2026 Congress

June 06, 2026

Cullinan Therapeutics to Host Immunology Day to Showcase Promising Initial Clinical Data in Autoimmune Diseases for CLN-978, a CD19 T Cell Engager, and Velinotamig, a BCMA T Cell Engager

May 26, 2026

Cullinan Therapeutics Receives FDA Orphan Drug Designation for CLN-049, a Novel FLT3xCD3 T Cell Engager, in Relapsed/Refractory Acute Myeloid Leukemia

May 19, 2026